Crinetics Pharmaceuticals Inc
CRNX
Market Cap$2.92B
Close$
$0.55
98.4% downside
Current Fair Value
98.4% downsideOvervalued by 98.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.92 Billion |
|---|---|
| Enterprise Value | $2.96 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.69 |
| Beta | 0.33 |
| Outstanding Shares | 93,791,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -7.86 |
|---|---|
| PEG | -14 |
| Price to Sales | - |
| Price to Book Ratio | 2.89 |
| Enterprise Value to Revenue | 2126.4 |
| Enterprise Value to EBIT | -6.98 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Crinetics Pharmaceuticals Inc
CEO: R. Scott Struthers